Boston Scientific Corp. Upgraded to “Overweight” at Oppenheimer (BSX)
Boston Scientific Corp. (NYSE:BSX) was upgraded by equities researchers at Oppenheimer from an “equal weight” rating to an “overweight” rating in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm currently has a $15.00 price objective on the stock. Oppenheimer’s target price indicates a potential upside of 25.73% from the company’s current price.
In other Boston Scientific Corp. news, Director Ernest Mario sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.06, for a total value of $120,600.00. Following the transaction, the director now directly owns 384,959 shares of the company’s stock, valued at approximately $4,642,606. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
BSX has been the subject of a number of other recent research reports. Analysts at Morgan Stanley upgraded shares of Boston Scientific Corp. to an “overweight” rating in a research note to investors on Monday. Separately, analysts at TheStreet downgraded shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, December 17th. Finally, analysts at Cowen and Company upgraded shares of Boston Scientific Corp. from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, December 6th. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $10.72.
Shares of Boston Scientific Corp. (NYSE:BSX) opened at 11.93 on Monday. Boston Scientific Corp. has a 1-year low of $5.92 and a 1-year high of $12.48. The stock’s 50-day moving average is $11.74 and its 200-day moving average is $11.19. The company’s market cap is $15.929 billion.
Boston Scientific Corp. (NYSE:BSX) last announced its earnings results on Thursday, October 24th. The company reported $0.17 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter last year, the company posted $0.16 earnings per share. Boston Scientific Corp.’s revenue was up .0% compared to the same quarter last year. Analysts expect that Boston Scientific Corp. will post $0.45 EPS for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.